Conference Coverage
Conference Coverage
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
Conference Coverage
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
Major Finding: Erlotinib resulted in a significant 63% reduction in the risk of progression, compared with standard chemotherapy (HR 0.37).Data...
Conference Coverage
Pemetrexed Continuation Maintenance Slows NSCLC Progression
Major Finding: Pemetrexed maintenance therapy plus best supportive care after pemetrexed/cisplatin induction reduced the risk of progression by 38...